Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Casuarina equisetifolia pollen extract is a non-standardized, biologic allergenic extract developed and marketed by ALK-Abello, Inc. The active ingredient is derived from the pollen of the *Casuarina equisetifolia* tree, also known as the Australian Pine or Beefwood tree. First approved in the United States in 1965, it is administered via subcutaneous injection. The product is used for both diagnostic allergy testing and for therapeutic hyposensitization (allergen immunotherapy) in patients with confirmed allergies to this specific pollen. The mechanism of action involves modulating the patient's immune response to the allergen, inducing a state of tolerance. This is achieved by promoting a shift in T-cell responses and stimulating the production of blocking IgG antibodies, which reduces the IgE-mediated allergic reaction upon natural exposure to the pollen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on casuarina equisetifolia pollen extract.